סיל - און 50 Izrael - hebrajski - Ministry of Health

סיל - און 50

rafa laboratories ltd - sildenafil 50 mg - film coated tablets - sildenafil - treatment of erectile dysfunction.

סיל - און 100 Izrael - hebrajski - Ministry of Health

סיל - און 100

rafa laboratories ltd - sildenafil 100 mg - film coated tablets - sildenafil - treatment of erectile dysfunction.

ציטוסאר 100 Izrael - hebrajski - Ministry of Health

ציטוסאר 100

pfizer pharmaceuticals israel ltd - cytarabine 100 mg / 5 ml - powder for solution for inj/inf - cytarabine - for leukemia.

ג'מסיטאבין אקטביס 200 מ"ג/בקבוקון Izrael - hebrajski - Ministry of Health

ג'מסיטאבין אקטביס 200 מ"ג/בקבוקון

devries & co. ltd - gemcitabine 200 mg/vial - powder for solution for infusion - gemcitabine - gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherap

ג'מסיטאבין אקטביס 1000 מ"ג/בקבוקון Izrael - hebrajski - Ministry of Health

ג'מסיטאבין אקטביס 1000 מ"ג/בקבוקון

devries & co. ltd - gemcitabine 1000 mg/vial - powder for solution for infusion - gemcitabine - gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherap

גמסיטאבין טבע  תמיסה מרוכזת Izrael - hebrajski - Ministry of Health

גמסיטאבין טבע תמיסה מרוכזת

abic marketing ltd, israel - gemcitabine as hydrochloride - תרכיז להכנת תמיסה לאינפוזיה - gemcitabine as hydrochloride 40 mg/ml - gemcitabine - gemcitabine - gemcitabine teva® concentrate is indicated for the palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer.gemcitabine teva® concentrate is indicated for the treatment of patients with bladder cancer at the invasive stage.breast cancer:gemcitabine teva® concentrate in combination with paclitaxel,is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant /neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.ovarian cancer:gemcitabine teva® concentrate in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma who have relapsed at least 6 months after platinum-based therapy.

אדריבלסטינה 10 מ"ג PFS Izrael - hebrajski - Ministry of Health

אדריבלסטינה 10 מ"ג pfs

pfizer pharmaceuticals israel ltd - doxorubicin hydrochloride 10 mg / 5 ml - solution for injection - doxorubicin - adriblastina has been used successfully to produce regression in a variety of neoplastic conditions, such as carcinoma of the breast, lung, bladder, thyroid, and also ovarian carcinomas, bone and soft-tissue sarcomas, hodgkin's lymphomas, neuroblastomas, wilms tumour, acute lymphoblastic leukaemia and acute myeloblastic leukaemia

אדריבלסטינה 50 מ"ג PFS Izrael - hebrajski - Ministry of Health

אדריבלסטינה 50 מ"ג pfs

pfizer pharmaceuticals israel ltd - doxorubicin hydrochloride 50 mg / 25 ml - solution for injection - doxorubicin - adriblastina has been used successfully to produce regression in a variety of neoplastic conditions, such as carcinoma of the breast, lung, bladder, thyroid, and also ovarian carcinomas, bone and soft-tissue sarcomas, hodgkin's and non- hodgkin's lymphomas, neuroblastomas, wilms tumour, acute lymphoblastic leukaemia and acute myeloblastic leukaemia

אוקסלטין 50 מ"ג Izrael - hebrajski - Ministry of Health

אוקסלטין 50 מ"ג

perrigo israel agencies ltd - oxaliplatin 50 mg - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for:- adjuvant treatment of stage iii (duke’s c) colon cancer after complete resection of primary tumour.-treatment of metastatic colorectal cancer.

אוקסלטין 100 מ"ג Izrael - hebrajski - Ministry of Health

אוקסלטין 100 מ"ג

perrigo israel agencies ltd - oxaliplatin 100 mg - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for:- adjuvant treatment of stage iii (duke’s c) colon cancer after complete resection of primary tumour.-treatment of metastatic colorectal cancer.